PFIZER INC Revenue from Contract with Customer, Excluding Assessed Tax
PFIZER INC (PFE) reported Revenue from Contract with Customer, Excluding Assessed Tax of $50.91 billion for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2024-02-22
- PFIZER INC revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $15.75B, a 2.68% decline year-over-year.
- PFIZER INC revenue from contract with customer, excluding assessed tax for the quarter ending 2022-10-02 was $22.64B, a 5.81% decline year-over-year.
- PFIZER INC revenue from contract with customer, excluding assessed tax for the quarter ending 2022-07-03 was $27.74B, a 46.79% increase year-over-year.
- PFIZER INC revenue from contract with customer, excluding assessed tax for the quarter ending 2022-04-03 was $25.66B, a 76.78% increase year-over-year.
- PFIZER INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $50.91B, a 44.53% decline from fiscal 2022.
- PFIZER INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $91.79B, a 24.66% increase from fiscal 2021.
- PFIZER INC revenue from contract with customer, excluding assessed tax for fiscal 2021 was $73.64B, a 76.79% increase from fiscal 2020.
- PFIZER INC revenue from contract with customer, excluding assessed tax for fiscal 2020 was $41.65B, a 1.82% increase from fiscal 2019.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $50.91B 10-K · filed 2024-02-22 | |||||||
| 2022-12-31 | $15.75B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $38.39B derived: sum of 2 quarters · filed 2024-02-22 | $66.13B derived: sum of 3 quarters · filed 2024-02-22 | $91.79B 10-K · filed 2024-02-22 | ||||
| 2022-10-02 | $22.64B 10-Q · filed 2022-11-09 | $50.38B derived: sum of 2 quarters · filed 2022-11-09 | $76.04B 10-Q · filed 2022-11-09 | $92.23B derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-07-03 | $27.74B 10-Q · filed 2022-08-10 | $53.40B 10-Q · filed 2022-08-10 | $69.59B derived: sum of 3 quarters · filed 2024-02-22 | $93.62B derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-04-03 | $25.66B 10-Q · filed 2022-05-11 | $41.85B derived: sum of 2 quarters · filed 2024-02-22 | $65.88B derived: sum of 3 quarters · filed 2024-02-22 | $84.78B derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2021-12-31 | $16.19B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $40.22B derived: sum of 2 quarters · filed 2024-02-22 | $59.12B derived: sum of 3 quarters · filed 2024-02-22 | $73.64B 10-K · filed 2024-02-22 | $81.29B 10-K · filed 2022-02-24 | |||
| 2021-10-03 | $24.04B 10-Q · filed 2022-11-09 | $24.09B 10-Q · filed 2021-11-12 | $42.93B derived: sum of 2 quarters · filed 2022-11-09 | $57.45B 10-Q · filed 2022-11-09 | $57.65B 10-Q · filed 2021-11-12 | $68.88B derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-07-04 | $18.90B 10-Q · filed 2022-08-10 | $18.98B 10-Q · filed 2021-08-12 | $33.41B 10-Q · filed 2022-08-10 | $33.56B 10-Q · filed 2021-08-12 | $44.84B derived: sum of 3 quarters · filed 2022-08-10 | $55.12B derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-04-04 | $14.52B 10-Q · filed 2022-05-11 | $14.58B 10-Q · filed 2021-05-13 | $25.94B derived: sum of 2 quarters · filed 2022-05-11 | $36.22B derived: sum of 3 quarters · filed 2022-05-11 | $46.08B derived: sum of 4 quarters · filed 2022-05-11 | |||
| 2020-12-31 | $11.43B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $21.70B derived: sum of 2 quarters · filed 2022-02-24 | $31.57B derived: sum of 3 quarters · filed 2022-02-24 | $41.65B 10-K · filed 2022-02-24 | $41.91B 10-K · filed 2021-02-25 | |||
| 2020-09-27 | $10.28B 10-Q · filed 2021-11-12 | $12.13B 10-Q · filed 2020-11-05 | $20.14B derived: sum of 2 quarters · filed 2021-11-12 | $30.22B 10-Q · filed 2021-11-12 | $35.96B 10-Q · filed 2020-11-05 | $32.07B derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-28 | $9.86B 10-Q · filed 2021-08-12 | $11.80B 10-Q · filed 2020-08-06 | $19.95B 10-Q · filed 2021-08-12 | $23.83B 10-Q · filed 2020-08-06 | $21.79B derived: sum of 3 quarters · filed 2022-02-24 | $34.47B derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-29 | $10.08B 10-Q · filed 2021-05-13 | $12.03B 10-Q · filed 2020-05-07 | $11.93B derived: sum of 2 quarters · filed 2022-02-24 | $24.61B derived: sum of 3 quarters · filed 2022-02-24 | $37.87B derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $1.84B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $14.52B derived: sum of 2 quarters · filed 2022-02-24 | $27.79B derived: sum of 3 quarters · filed 2022-02-24 | $40.91B 10-K · filed 2022-02-24 | $51.75B 10-K · filed 2020-02-27 | |||
| 2019-09-29 | $12.68B 10-Q · filed 2020-11-05 | $25.94B derived: sum of 2 quarters · filed 2020-11-05 | $39.06B 10-Q · filed 2020-11-05 | $40.22B derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $13.26B 10-Q · filed 2020-08-06 | $26.38B 10-Q · filed 2020-08-06 | $27.54B derived: sum of 3 quarters · filed 2021-02-25 | $40.84B derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $13.12B 10-Q · filed 2020-05-07 | $14.27B derived: sum of 2 quarters · filed 2021-02-25 | $27.57B derived: sum of 3 quarters · filed 2021-02-25 | $41.04B derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $1.16B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $14.45B derived: sum of 2 quarters · filed 2021-02-25 | $27.92B derived: sum of 3 quarters · filed 2021-02-25 | $40.83B 10-K · filed 2021-02-25 | $53.65B 10-K · filed 2019-02-28 | |||
| 2018-09-30 | $13.30B 10-Q · filed 2019-11-07 | $26.76B derived: sum of 2 quarters · filed 2019-11-07 | $39.67B 10-Q · filed 2019-11-07 | $53.37B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-07-01 | $13.47B 10-Q · filed 2019-08-08 | $26.37B 10-Q · filed 2019-08-08 | $40.08B derived: sum of 3 quarters · filed 2020-02-27 | $53.24B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-04-01 | $12.91B 10-Q · filed 2019-05-09 | $26.61B derived: sum of 2 quarters · filed 2020-02-27 | $39.78B derived: sum of 3 quarters · filed 2020-02-27 | $52.67B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $13.70B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $26.87B derived: sum of 2 quarters · filed 2020-02-27 | $39.77B derived: sum of 3 quarters · filed 2020-02-27 | $52.55B 10-K · filed 2020-02-27 | ||||
| 2017-10-01 | $13.17B 10-Q · filed 2018-11-08 | $26.06B derived: sum of 2 quarters · filed 2018-11-08 | $38.84B 10-Q · filed 2018-11-08 | |||||
| 2017-07-02 | $12.90B 10-Q · filed 2018-08-09 | $25.68B 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | $52.82B 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |